Avandia administration for 6-12 weeks (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00006185 (ClinicalTrials.gov) | September 1999 | 22/8/2000 | Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome | Cellular Mechanisms for Metabolic Dysfunction in HIV | HIV Infections;Lipodystrophy;Insulin Resistance | Drug: Avandia administration for 6-12 weeks | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Completed | 18 Years | 55 Years | Both | Phase 1 | United States |